A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis

医学 阿纳基纳 秋水仙碱 优势比 随机对照试验 心包炎 内科学 胃肠病学 安慰剂 不利影响 荟萃分析 病理 疾病 替代医学
作者
María Melendo‐Viu,Álvaro Marchán-López,Carmen Jiménez López-Guarch,Sergio Raposeiras‐Roubín,Emad Abu‐Assi,Rocío Tello de Meneses,Fernando Arribas,Adrián Vladimir Hernández,Héctor Bueno
出处
期刊:Trends in Cardiovascular Medicine [Elsevier BV]
卷期号:33 (5): 319-326 被引量:20
标识
DOI:10.1016/j.tcm.2022.02.001
摘要

Acute idiopathic pericarditis (AIP) is a benign inflammatory condition associated with high recurrence rates. Non-steroidal anti-inflammatory drug (NSAIDs) and colchicine are the recommended therapies. Our objective was to systematically assess effects of pharmacological therapies on recurrences or treatment failure in patients with first and subsequent AIP episodes. PubMed, BioMedCentral, Cochrane, Clinicaltrials.gov, Google Scholar and EMBASE (Ovid) were searched up to April 2020 for randomized controlled trials (RCT) evaluating NSAIDs, indomethacin, colchicine, steroids, intravenous immunoglobulins, immunomodulators, or interleukin receptor antagonists in adult patients with acute episode of idiopathic pericarditis. Mantel-Haenzel random effects models were used for meta-analyses, and effects were reported as odds ratios (ORs) and their 95% confidence intervals (CI). Six RCTs of colchicine plus NSAIDs (n=914 patients) and one RCT of anakinra (n=21) were found. No RCTs testing NSAIDs or corticosteroids were identified. Colchicine plus NSAIDs and anakinra significantly reduced recurrence (OR 0.37; 95%CI 0.27-0.51; and OR 0.02; 95%CI, 0.00-0.32, respectively). Colchicine plus NSAIDs also reduced treatment failure (OR 0.29; 95%CI 0.21-0.41). No differences in adverse events between colchicine and placebo were found (OR 1.16; 95%CI 0.72 to 1.86). In conclusion, Colchicine plus NSAIDS and anakinra are efficacious for preventing AIP recurrences. Colchicine reduces treatment failure as well. Although its use is supported by clinical experience, no solid evidence is currently available for the role of NSAIDs or steroids in the treatment of AIP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
王明初完成签到 ,获得积分10
1秒前
dASDA完成签到,获得积分10
1秒前
全能完成签到,获得积分10
1秒前
缓慢的咖啡完成签到,获得积分10
1秒前
hzs完成签到,获得积分10
2秒前
2秒前
温馨发布了新的文献求助10
2秒前
2秒前
淡然的眼神完成签到,获得积分10
3秒前
3秒前
依壹完成签到,获得积分10
4秒前
kkkwang3完成签到,获得积分10
4秒前
wycpavel完成签到,获得积分10
4秒前
4秒前
英姑的应助被孙朱珠采纳,获得10
4秒前
爆米花的应助被六六采纳,获得10
5秒前
鱼鱼鱼完成签到,获得积分10
5秒前
复杂的傲松完成签到,获得积分10
5秒前
5秒前
L91完成签到,获得积分10
6秒前
朝俞完成签到 ,获得积分10
6秒前
无字诉题发布了新的文献求助10
6秒前
6秒前
6秒前
斯文败类的应助被guoguo采纳,获得10
6秒前
shelemi完成签到,获得积分10
7秒前
7秒前
7秒前
子卿发布了新的文献求助10
8秒前
无限凛完成签到 ,获得积分10
8秒前
vv完成签到,获得积分10
8秒前
8秒前
8秒前
8秒前
9秒前
asdfsdafg发布了新的文献求助10
9秒前
DW的应助被动人的从云采纳,获得10
9秒前
科研通AI6.4的应助被放手一搏采纳,获得10
9秒前
神勇问安完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042